Search
for
Sort by
Research 571–600 of 582
- Effectiveness and safety of the ablative fractional 2940-nm Er: YAG laser for the treatment of androgenetic alopecia
- Cell death as an architect of adult skin stem cell niches
- Use of fractionated laser therapy for the treatment of androgenetic alopecia: a systematic review and meta-analysis
- A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function
- Hair disorders associated with post-COVID-19 infection in females: a cross-sectional study
- The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study
- Reproductive performance of hair ewes and rams implanted with melatonin previous to the anestrus season in northwest Mexico
- An update on plants for hair growth promoting activities
- Symptoms of hypogonadism caused by 5α-reductase inhibitors
- African Hair
- Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies
- Notes from the Editor Emeritus: Coincidental Epigenetics or Post-Finasteride Syndrome (PFS)?
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
- 5α-Reductase Inhibitors (5ARIs) and Male Reproduction
- PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
- Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- The connection of 5-alpha reductase inhibitors to the development of depression
- Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
- Identification of Beta-Sitosterol and Stigmasterol as Possible Inhibitors of 5 Alpha-Reductase 1: An In-Silico Study
- 5ARIs and PSA: Evidences
- Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- 5ARI and PSA: open questions
- Sponsored Lecture 3 : Updates on 5 alpha-rers(5ARIs) for the treatment of male pattern hair loss(MPHL)
- LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
- Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy
- Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2
- Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID‐19 pandemic?
- Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
- HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitors